Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-42344 in Healthy Participants (Phase 1)
NCT05202379Phase 1Completed
- Sponsor
- Cocrystal Pharma
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CC-42344 in Influenza A (IAV) (9 cohorts), sponsored by Cocrystal Pharma. Primary endpoints: Treatment-Emergent Adverse Events (SAD) at 16 days, Clinically Significant Laboratory Abnormalities (SAD) at 16 days and 6 more. Started Feb 2022; status: completed.
02
Drugs
CC-42344
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05202379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202379.